Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Up 5.7% in July

Celldex Therapeutics, Inc. (NASDAQ:CLDX) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 7,390,000 shares, a growth of 5.7% from the June 30th total of 6,990,000 shares. Based on an average trading volume of 641,800 shares, the short-interest ratio is currently 11.5 days.

Celldex Therapeutics Price Performance

NASDAQ:CLDX traded down $0.56 during mid-day trading on Thursday, reaching $37.55. The stock had a trading volume of 801,615 shares, compared to its average volume of 796,661. The business’s 50 day moving average is $36.76 and its 200 day moving average is $39.16. Celldex Therapeutics has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The stock has a market cap of $2.47 billion, a P/E ratio of -13.37 and a beta of 1.58.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.11. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Equities analysts expect that Celldex Therapeutics will post -2.39 EPS for the current year.

Insider Activity

In related news, VP Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the transaction, the vice president now directly owns 9,074 shares of the company’s stock, valued at $305,249.36. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, VP Elizabeth Crowley sold 38,597 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the completion of the sale, the vice president now directly owns 9,074 shares in the company, valued at $305,249.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Diane C. Young sold 45,000 shares of Celldex Therapeutics stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the completion of the transaction, the senior vice president now owns 2,115 shares in the company, valued at approximately $74,574.90. The disclosure for this sale can be found here. Insiders sold 266,332 shares of company stock worth $9,155,821 over the last three months. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Panagora Asset Management Inc. bought a new stake in shares of Celldex Therapeutics during the 2nd quarter worth $4,380,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Celldex Therapeutics by 40.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,111 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 4,093 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Celldex Therapeutics by 14.6% in the second quarter. Bank of New York Mellon Corp now owns 230,162 shares of the biopharmaceutical company’s stock worth $8,518,000 after purchasing an additional 29,324 shares during the period. AlphaCentric Advisors LLC lifted its position in shares of Celldex Therapeutics by 23.4% during the 2nd quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company’s stock worth $1,758,000 after purchasing an additional 9,000 shares during the last quarter. Finally, Values First Advisors Inc. grew its holdings in Celldex Therapeutics by 8.3% in the 2nd quarter. Values First Advisors Inc. now owns 21,319 shares of the biopharmaceutical company’s stock valued at $789,000 after buying an additional 1,627 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CLDX. Wolfe Research began coverage on Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Tuesday. Finally, Stifel Nicolaus began coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price objective for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $62.17.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.